Skip to main content

Remifentanil Injection Shortage

Last Updated: November 27, 2023
Status: Current

Products Affected - Description
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
    • Remifentanil lyophilized powder for injection, Hikma, 1 mg, vial, 10 count, NDC 00143-9391-10
Reason for the Shortage
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Viatris did not provide a reason for the shortage.
Available Products
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 1 mg, vial, 10 count, NDC 72078-0034-01
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 2 mg, vial, 10 count, NDC 72078-0035-02
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 5 mg, vial, 10 count, NDC 67457-0198-10
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
    • Remifentanil lyophilized powder for injection, Hikma, 2 mg, vial, 10 count, NDC 00143-9392-10
    • Remifentanil lyophilized powder for injection, Hikma, 5 mg, vial, 10 count, NDC 00143-9393-10

Estimated Resupply Dates

    • Fresenius Kabi has remifentanil 5 mg vials on back order and the company estimates a release date of late-November to early-December 2023.
    • Hikma has remifentanil 1 mg vials on back order and the company cannot estimate a release date.

Updated

Updated November 27, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 22, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.